Miflonide Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, modifying gene expression to suppress the production of inflammatory mediators, reduce immune cell infiltration, and stabilize mast cells. This anti‑inflammatory action diminishes airway edema and hyper‑responsiveness, leading to better airflow and symptom control.

The specific dose of Miflonide Breezhaler is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the healthcare provider.

Safety data for budesonide inhalation in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as small amounts may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Miflonide Breezhaler delivers budesonide via the Breezhaler device, offering consistent fine‑particle dosing and low systemic exposure compared with some older inhaled steroids. Its pharmacokinetic profile provides effective airway anti‑inflammation while minimizing oral bioavailability, making it comparable to other high‑potency inhaled glucocorticoids such as fluticasone.

Store Miflonide Breezhaler at ambient temperature, below 25 °C, in its original packaging. Keep the device away from moisture and direct sunlight. Do not expose the inhaler to extreme heat or freeze it, as this may affect powder integrity and dose consistency.

The patient inhales the powdered budesonide using the Breezhaler device. After loading a dose, the patient exhales fully, places the mouthpiece in the mouth, and inhales forcefully and deeply. The device should be cleaned regularly according to the manufacturer’s instructions to maintain optimal performance.

Serious risks include adrenal suppression, which can lead to fatigue, hypotension, or electrolyte imbalance, and paradoxical bronchospasm, a sudden worsening of breathing. Infections such as pneumonia may also occur more frequently. Patients should be educated to report severe fatigue, unexplained weakness, or worsening respiratory symptoms promptly.

Miflonide Breezhaler is contraindicated in patients with known hypersensitivity to budesonide or any component of the formulation. It should also be avoided in individuals with untreated active infections of the respiratory tract, as the anti‑inflammatory effect may mask symptoms and worsen the infection.